O7-2 FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13)

Abstract

FOLFOXIRI plus bevacizumab (bev) or panitumumab has been shown to be superior in terms of early tumor shrinkage and depth of response (DpR) compared to doublet combinations in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC). We performed a randomized phase II study, DEPER trial (JACCRO CC-13), to investigate the efficacy and safety of cetuximab (cet) vs bev plus modified (m)-FOLFOXIRI (irinotecan 150mg/m2, oxaliplatin 85mg/m2, 5-FU 2400mg/m2) in previously untreated mCRC pts with RAS wt tumors.